GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

As 2025 ushers in a new era of weight loss resolutions, many Americans are abandoning traditional gym-first approaches in ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

去年这个时候，人们还在争论诺和诺德（NVO.US）的Wegovy和礼来（LLY.US）的Zepbound是减肥的捷径还是医学上的突破。但是，随着大量数据表明这些药物的健康益处不仅仅是减少肥胖——包括减轻心脏病、糖尿病、慢性肾病和睡眠呼吸暂停——大多数人似乎终于接受了它们潜在的巨大社会价值。

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

近年来，减肥药物市场一度成为投资者关注的焦点，随着Novo Nordisk的Wegovy和Eli ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

两项重磅试验2025年揭晓 ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...